Please login to the form below

Not currently logged in
Email:
Password:

Millennium begins phase III trial for Velcade myeloma combination therapy

Millennium Pharmaceuticals has revealed it will expand the use of its Velcade blood cancer treatment

US-headquartered Millennium Pharmaceuticals has revealed it will expand the use of Velcade (bortezomib), its multiple myeloma or blood cancer treatment.

The injectable drug, which is being co-developed by Millennium and J&J Pharmaceutical Research & Development, is currently approved for the treatment of patients with multiple myeloma who have received at least one prior therapy. Velcade is also indicated for the treatment of patients with mantle cell lymphoma who have received at least one prior therapy.

The phase III UPFRONT trial will determine the most effective Velcade-based combination therapy with approved agents for the treatment of newly diagnosed multiple myeloma patients, ineligible for stem cell transplantation.

The trial's primary end point is progression-free survival and secondary endpoints including duration of response, overall survival and overall safety / tolerability. The three treatment arms are Velcade and Dexamethasone (VD); Velcade, Thalidomide and Dexamethasone (VTD); and Velcade, Melphalan and Prednisone (VMP). About 500 patients are expected to be enrolled in the trial and will remain on treatment for up to one year.

In FY06, US sales of Velcade were approximately USD 220.5m, which represented approximately 45 per cent of Millennium's total revenue for 2006. This compares with FY05 sales of approximately USD 192.1m, which represented approximately 34 per cent of total revenue for that time period.

18th July 2007

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
GCI Health

GCI Health London is a young, vibrant powerhouse in the European industry with a mission to redefine healthcare communications, starting...

Latest intelligence

Combined immunotherapies – potential and pitfalls
‘Combining therapeutic compounds is the first logical step towards better results, namely higher rates of patients responding to treatment, with deeper and more sustained responses’...
Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...
What is blockchain and why should i care - Richard Springham
Four Health - Emerging Technologies The power of blockchain lies in the fact it can prove that a unique event occurred at a certain time with out the need to...

Infographics